Prime Capital Investment Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $824K | Buy |
9,939
+2,729
| +38% | +$226K | 0.01% | 508 |
|
|
2025
Q1 | $585K | Buy |
7,210
+1,586
| +28% | +$129K | 0.01% | 630 |
|
|
2024
Q4 | $506K | Sell |
5,624
-90
| -2% | -$8.11K | 0.01% | 564 |
|
|
2024
Q3 | $565K | Sell |
5,714
-377
| -6% | -$37.2K | 0.01% | 554 |
|
|
2024
Q2 | $565K | Sell |
6,091
-1,636
| -21% | -$152K | 0.01% | 548 |
|
|
2024
Q1 | $733K | Buy |
7,727
+1,263
| +20% | +$120K | 0.01% | 526 |
|
|
2023
Q4 | $577K | Buy |
6,464
+2,228
| +53% | +$199K | 0.01% | 543 |
|
|
2023
Q3 | $309K | Buy |
4,236
+226
| +6% | +$16.5K | 0.01% | 574 |
|
|
2023
Q2 | $334K | Buy |
+4,010
| New | +$334K | 0.01% | 574 |
|
|
2023
Q1 | – | Sell |
-7,894
| Closed | -$655K | – | 660 |
|
|
2022
Q4 | $655K | Buy |
7,894
+5,194
| +192% | +$431K | 0.02% | 293 |
|
|
2022
Q3 | $214K | Buy |
+2,700
| New | +$214K | 0.01% | 368 |
|